Pharming Group has started enrolment in a clinical trial of Ruconest, a recombinant human C1 inhibitor, for the treatment of hospitalised Covid-19 patients.

The randomised, controlled, investigator-initiated study is recruiting patients with Covid-19-associated severe pneumonia at the University Hospital Basel in Basel, Switzerland.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In April this year, the company announced promising data from a compassionate use programme at the University Hospital Basel.

As part of the programme, five patients with Covid-19-related severe pneumonia who did not improve on standard therapies such as hydroxychloroquine and lopinavir/ritonavir were given Ruconest.

After treatment, fever resolved in four of the five patients within two days. A significant decrease was also observed in laboratory markers of inflammation (CRP, IL-6).

These four patients were discharged from the hospital after fully recovering, while one patient had increased oxygen requirement and was admitted to the ICU, but later fully recovered.

Based on these findings, the company launched a larger investigator-initiated trial to assess the full extent of the role of its drug in treating severe pneumonia caused by Covid-19.

If positive data is obtained in the clinical trial, Pharming may conduct additional studies of Ruconest in patients with other diseases that lead to severe respiratory or other organ failure complications.

Pharming chief medical officer Bruno Giannetti said: “Ruconest’s multiple interactions with key inflammation pathways therefore make it a promising candidate to prevent the severe complications observed in Covid-19 patients.

“This investigator-initiated clinical trial in partnership with Dr Michael Osthoff will be important, not only for the treatment of pneumonia as a result of Covid-19 infection, but will also provide key insight into the future treatment of complement system influenced diseases.”

The drug is indicated in the US and EU to treat hereditary angioedema.